CNW Group2026. 05. 28. 05:00
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $5.5 · 4 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 30. | After market close (AMC) | — | — | — | $197.71M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.04 | — | — | $184.48M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.21 | — | — | $558.85M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.21 | — | — | $382.05M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 11. 04. | B of A Securities | — | Downgrade | Neutral → Underperform | — | B of A Securities: Neutral → Underperform |
| 2025. 10. 03. | Baird | — | Maintain | Neutral → Neutral | — | Baird: Neutral |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
No holdings data to show.
See new positions, full exits, and weight changes.
